A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 777-779

  Metcalfe, K A ^a,b   Poll, A ^b   Royer, R ^b   Nanda, S ^b   Llacuachaqui, M ^b   Sun, P ^b   Narod, S A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CLINICAL ARTICLE; COMPARATIVE STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HUMAN; JEW; OVARY CANCER; PATIENT REFERRAL; POPULATION GENETICS; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; GERM-LINE MUTATION; GUIDELINE ADHERENCE; HUMANS; JEWS; MIDDLE AGED; ONTARIO; OVARIAN NEOPLASMS;

EID: 84883145914     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.309     Document Type: Article

References (10)

1. Bosch N, Junyent N, Gadea N, Brunet J, Ramon Y, Cajal T, Torres A, Graña B, Velasco A, Darder E, Mensa I, Balmaña J (2012) What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? Breast 21: 755-760.
2. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39: 611-614.
3. Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, Bradley L, Armel S, Sun P, Narod SA (2009) Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol 112: 68-72.
4. Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA (2012) Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 133: 735-740.
5. Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA (2010a) Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 78: 411-417.
6. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010b) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28: 387-391.
7. NCCN (2012) NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Vol. 2012. National Comprehensive Cancer Network.
8. Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, Hanna D, Narod SA (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20: 352-357.
9. Roa BB, Boyd AA, Vocik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185-187.
10. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408.